Kygent Therapeutics

Kygent Therapeutics is a biotechnology company focused on the development of next-generation, conditionally active cytokine therapies for oncology. The company's proprietary platform is designed to engineer cytokines that remain inactive in systemic circulation but become potent immune activators specifically within the tumor microenvironment. This approach aims to harness the powerful anti-tumor properties of cytokines while significantly reducing the severe systemic toxicities that have historically limited their clinical utility. Kygent is currently advancing a pipeline of engineered cytokine candidates targeting various solid tumor indications.